The results of this study provide evidence that the IITQ is a reliable instrument for assessing a broad range of patient reported outcomes (PRO) in patients with type 1 or type 2 diabetes using inhaled insulin. The gene discussed is INS; the disease is type 2 diabetes mellitus.